Kymera Therapeutics, Inc.
As of Oct 22, 2026, Kymera Therapeutics is in Stage 2, the uptrend phase, now in week 17 (since Jun 24, 2026). It closed at $110.85, 12.9% below its 52-week high and above its 200-day average, which is rising.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is KYMR early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KYMR among Biotechnology53rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …53 | KYMR | Stage 2 · wk 17 | 94 | −4.0% |
Kymera Therapeutics: quick answers
What stage is Kymera Therapeutics in?
As of Oct 22, 2026, Kymera Therapeutics (KYMR) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 24, 2026 and is in week 17. What the four stages mean
Is Kymera Therapeutics in an uptrend?
Yes. Kymera Therapeutics is in a Stage 2 uptrend. It trades 16.6% above its 200-day average, which is rising.
How far is Kymera Therapeutics from its 52-week high?
Kymera Therapeutics closed at $110.85 on Oct 22, 2026, 12.9% below its 52-week high of $127.31. Its 52-week low is $55.80.
How has Kymera Therapeutics performed over the past year?
As of Oct 22, 2026, Kymera Therapeutics is up 90.1% over the past year and up 52.4% so far in 2026.
Which sector and industry is Kymera Therapeutics in?
Kymera Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.